Skip to content

Vera Therapeutics VERA Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

Immunome logo
ImmunomeIMNM
$150K+30.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$1.88M-34.6%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$26K+18.2%
TG Therapeutics logo
TG TherapeuticsTGTX
$573K+26.5%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$204K-8.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's non-cash lease expense?
Vera Therapeutics (VERA) reported non-cash lease expense of $116K in Q1 2026.
How has Vera Therapeutics's non-cash lease expense changed year-over-year?
Vera Therapeutics's non-cash lease expense decreased by 74.6% year-over-year, from $457K to $116K.
What does non-cash lease expense mean?
Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.